SEARCH
Search Details
UEDA YukiUniversity Hospital / Hepato-Biliary-Pancreatic SurgeryAssistant Professor
Research activity information
■ Paper- PURPOSE: Glypican-3 (GPC3), highly expressed in the most common liver cancer hepatocellular carcinoma (HCC) but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired PET diagnostic and alpha particle therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. EXPERIMENTAL DESIGN: Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase-expressing liver cancer models (HepG2 and Hep3B). Micro-scale co-localization of the pair was validated using quantitative particle identification (QPID) spectral autoradiography. Preclinical trial of therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histological confirmation, and overall survival. RESULTS: The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200 percent injected activity per gram [%IA/g]) and high overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses, and improved overall survival compared to control cohorts. We also observed efficacy in orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. CONCLUSIONS: We show GPC3-specific PET imaging can predict and assess response to GPC3-targeted alpha particle therapy in orthotopic liver cancer models. This approach can address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.Sep. 2026, Clinical cancer research : an official journal of the American Association for Cancer Research, English, International magazineScientific journal
- BACKGROUND: The AirSeal® insufflation system (ASIS) provides stable pneumoperitoneum during minimally invasive pancreaticoduodenectomy (MIPD), but its impact on postoperative venous thromboembolism (VTE) remains unclear. METHODS: We retrospectively analyzed 142 consecutive patients who underwent MIPD between May 2021 and January 2026. Patients were divided into an ASIS group and a standard insufflation system (StIS) group. In both groups, pneumoperitoneum pressure was maintained at 10 mmHg. The primary outcome was VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), occurring within 14 days after surgery. RESULTS: Among 142 patients, 48 underwent MIPD with ASIS and 94 with StIS. VTE occurred in 12 patients (8.5%) and was significantly more frequent in the ASIS group (16.7% vs. 4.3%, p = 0.012). VTE tended to occur earlier in the ASIS group (median 2.5 vs. 7 days, p = 0.064). Five patients in the ASIS group developed PE including four symptomatic cases, whereas all VTE events in the StIS group were asymptomatic. Multivariable analysis identified ASIS use (odds ratio [OR] 5.67, 95% confidence interval [CI] 1.26-33.2) and open conversion (OR 6.42, 95% CI 1.59-26.6) as independent risk factors for VTE. CONCLUSIONS: ASIS use at a pneumoperitoneum pressure of 10 mmHg was independently associated with an increased risk of early postoperative VTE after MIPD. Further investigation of lower-pressure or intermittent desufflation strategies is warranted.Sep. 2026, Surgical endoscopy, English, International magazineScientific journal
- Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related mortality worldwide. Although HCC-selective diagnostics and treatments remain limited for late-stage disease, tumor-targeted radiopharmaceuticals offer a promising strategy to address this unmet need. Here, we identify tetraspanin-8 (TSPAN8) as a novel tumor-selective immuno-PET imaging target in HCC. Methods: TSPAN8 expression was analyzed in 4 HCC cell lines (Huh7, Hep3B, SNU182, and SNU449) and 1 hepatoblastoma cell line (HepG2) using Western blotting and flow cytometry. The binding kinetics of a monoclonal antibody (α-hTSPAN8) against human TSPAN8 were evaluated using enzyme-linked immunosorbent assay and biolayer interferometry. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9-mediated gene editing was used to generate TSPAN8-knockout (TSPAN8-) variants in Huh7 and Hep3B cells, validated through flow cytometry, immunofluorescence, and immunohistochemistry of xenograft tissues. Subcutaneous TSPAN8+ and TSPAN8- xenografts were established in athymic NU/NU mice. For imaging studies, α-hTSPAN8 was conjugated with deferoxamine (DFO) and radiolabeled with 89Zr, a positron emitter. Tumor-specific uptake of [89Zr]Zr-DFO-α-hTSPAN8 was evaluated by in vivo PET/CT imaging at 48, 72, and 144 h after injection, followed by an ex vivo biodistribution analysis. Results: Huh7 and Hep3B cells exhibited high membrane TSPAN8 expression. The α-hTSPAN8 antibody demonstrated nanomolar affinity and specific binding to TSPAN8+ cells. We synthesized both DFO-α-hTSPAN8 and [89Zr]Zr-DFO-α-hTSPAN8 to greater than 98% purity and greater than 99% labeling efficiency, respectively, with the radioconjugate exhibiting excellent stability in human serum at 37 °C. In vivo PET/CT imaging and biodistribution studies showed significant and selective tracer accumulation in TSPAN8+ tumors, with negligible uptake in TSPAN8- controls. Conclusion: Our findings establish TSPAN8 as a promising target for radiopharmaceutical development for the treatment of HCC.Mar. 2026, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 67(3) (3), 410 - 415, English, International magazineScientific journal
- Unexpected vascular lesions may complicate standard laparoscopic pancreatic procedures. We report a case of mucinous cystic neoplasm (MCN) treated with laparoscopic spleen-preserving distal pancreatectomy (LSPDP) in which unrecognized immunoglobulin G4 (IgG4)-related periarteritis of the splenic artery caused difficulty during vascular division. A 76-year-old woman underwent LSPDP for MCN. Preoperative computed tomography demonstrated circumferential soft-tissue thickening along the splenic artery. Intraoperatively, the splenic artery was deeply embedded within the pancreatic parenchyma, making the Kimura technique impractical; therefore, the Warshaw technique was selected. However, the splenic artery demonstrated marked circumferential wall thickening, precluding safe division with ligation or clipping alone. The artery was ultimately divided using a vascular stapler. Histopathological examination revealed low-grade MCN and IgG4-related periarteritis involving the splenic artery. This case highlights that IgG4-related periarteritis should be considered when unexplained perivascular soft-tissue thickening is identified preoperatively, as it may significantly alter intraoperative strategy during LSPDP.2026, Asian journal of endoscopic surgery, 19(1) (1), e70387, English, Domestic magazineScientific journal
- While radiopharmaceutical therapy (RPT) has become part of the standard-of-care for patients with advanced prostate cancers and neuroendocrine tumors (NETs), cures are elusive and normal tissue toxicity remain a challenge. Chemical groups susceptible to cleavage by enzymes present in tumors, tumor microenvironment or in normal tissues, have the potential to improve the therapeutic index for RPT. Using DOTA-TATE as an example and drawing from strategies used to develop antibody-drug conjugates, we designed, and synthesized, a chemically diverse series of linkers between the chelator (DOTA) and the targeting vector (TATE). Of the 10 agents we tested, two with cleavable linker domains reduced kidney retention compared to DOTA-TATE: the previously reported DOTA-MVK(ε)-TATE, and a novel agent bearing cleavable beta-galactose (β-Gal) unit, DOTA-β-Gal-TATE. In murine models of NETs, positron emission tomography (PET) was used to image yttrium-86 (86Y)-labeled variants and show that, while the 86Y-DOTA-MVK(ε)-TATE exhibits similar tumor uptake to the parent non-cleavable 86Y-DOTA-TATE, 86Y-DOTA-β-Gal-TATE shows enhanced tumor uptake, resulting in up to 10-fold improvement in the tumor-to-kidney ratios compared to 86Y-DOTA-TATE. In vitro and in vivo studies confirm high efficiency, enzyme-specific cleavage of 86Y-DOTA-MVK(ε)-TATE and 86Y-DOTA-β-Gal-TATE, supporting a key role for cleavable linker chemistry in the observed outcomes. RPT studies using actinium-225 (225Ac)-labeled variants confirm that all agents are therapeutically effective and well tolerated. While both cleavable variants exhibit superior local control, overall survival, and more favorable toxicity profile when compared with 225Ac-DOTA-TATE, 225Ac-DOTA-β-Gal-TATE demonstrated lower nephrotoxicity. Our findings suggest a potentially generalizable strategy for improving the pharmacokinetics of radiopharmaceutical therapy agents.Sep. 2025, bioRxiv : the preprint server for biology, English, International magazineScientific journal
- Radiation exposure can result in various complications influenced by factors such as dose, the amount of tissue exposed, and the type of tissue exposed. Radiation-induced liver injury (RILI) is a concern in cancer patients receiving thoracic and upper abdominal radiation, but it can also be a risk for civilians exposed to radiation in a nuclear event. RILI can lead to organ dysfunction or death; a deeper understanding of how radiation causes damage to normal tissue could pave the way for new treatments. In our study, we focused on the effects of radiation on the two main liver cell types: liver sinusoidal endothelial cells (LSECs) and hepatocytes. We exposed these cells to different doses of radiation (2, 4 or 8 Gy) as well as a sham irradiation (0 Gy) control. Proteins were extracted at 30 min, 6 h and 24 h postirradiation and analyzed using reverse phase protein array (RPPA). We observed changes to the Hepatic fibrosis signaling pathway, IL-8 signaling, and S100 family signaling pathways across multiple doses and time points in LSECs. In hepatocytes, radiation affected different pathways; we see changes in the Th1 and Th2 signaling pathways and the IL-10 signaling pathway. These pathways are critical in mediating the immune response, with Th1 being associated with pro-inflammatory responses and Th2 with anti-inflammatory responses. Hub proteins from protein-protein interaction (PPI) networks across all time points for both LSECs and hepatocytes highlighted EGFR as a top-ranked protein, indicating the potential role in mitigating radiation damage in liver cells. Herein, we showed alterations in protein expression after RILI using RPPA at early time points (hours to days) to determine potentially targetable molecular pathways. We further highlighted potential therapeutic protein markers, including EGFR, as an example of the potential utility of RPPA in target discovery.May 2025, Radiation research, 203(5) (5), 293 - 303, English, International magazineScientific journal
- Both cancer patients receiving radiotherapy and civilians in a mass casualty nuclear event may suffer from radiation induced damage to organ systems. Radiation induced liver disease (RILD) can cause acute and long-term organ dysfunction that potentially leads to death. The objective of this study was to ascertain the validity of a liver quad-culture chip, a micro-physiological system comprising primary human hepatocytes and non-parenchymal cells (NPCs), including liver sinusoidal endothelial cells, hepatic stellate cells (HSCs), and Kupffer cells, as a model for RILD. The radiation exposure to the chip model resulted in DNA damage and cellular senescence of hepatocytes and NPCs. We observed metabolic dysfunction, inflammation, endothelial dysfunction, and HSCs activation. Whole genome sequencing revealed gene alterations in pathways relevant to RILD, as well as the potential efficacy of N-acetylcysteine amide (NACA) against RILD. NACA exhibited the capacity to mitigate DNA damage and cellular senescence and decreased the impact of radiation exposure on other pathophysiological changes. CDKN1A and miR-34a-5p were validated as useful radiation response and treatment efficacy biomarkers. These findings highlight the potential of the liver quad-culture chip as an effective model for investigating the microenvironment in RILD and for evaluating the efficacy of therapeutic countermeasures and biomarkers.Apr. 2025, Scientific reports, 15(1) (1), 12414 - 12414, English, International magazineScientific journal
- Radiation exposure in a therapeutic setting or during a mass casualty event requires improved medical triaging, where the time to delivery and quantity of medical countermeasures are critical to survival. Radiation-induced liver injury (RILI) and fibrosis can lead to death, but clinical symptoms manifest late in disease pathogenesis and there is no simple diagnostic test to determine RILI. Because animal models do not completely recapitulate clinical symptoms, we used a human liver-on-a-chip model to identify biomarkers of RILI. The goals of this study were: 1. to establish a microfluidic liver-on-a-chip device as a physiologically relevant model for studying radiation-induced tissue damage; and 2. to determine acute changes in RNA expression and biological pathway regulation that identify potential biomarkers and mechanisms of RILI. To model functional human liver tissue, we used the Emulate organ-on-a-chip system to establish a co-culture of human liver sinusoidal endothelial cells (LSECs) and hepatocytes. The chips were subject to 0 Gy (sham), 1 Gy, 4 Gy, or 10 Gy irradiation and cells were collected at 6 h, 24 h, or 7 days postirradiation for RNA isolation. To identify significant expression changes in messenger RNA (mRNA) and long non-coding RNA (lncRNA), we performed RNA sequencing (RNASeq) to conduct whole transcriptome analysis. We found distinct differences in expression patterns by time, dose, and cell type, with higher doses of radiation resulting in the most pronounced expression changes, as anticipated. Ingenuity Pathway Analysis indicated significant inhibition of the cell viability pathway 24 h after 10 Gy exposure in LSECs but activation of this pathway in hepatocytes, highlighting differences between cell types despite receiving the same radiation dose. Overall, hepatocytes showed fewer gene expression changes in response to radiation, with only 3 statistically significant differentially expressed genes at 7 days: APOBEC3H, PTCHD4, and GDNF. We further highlight lncRNA of interest including DINO and PURPL in hepatocytes and TMPO-AS1 and PRC-AS1 in LSECs, identifying potential biomarkers of RILI. We demonstrated the potential utility of a human liver-on-a-chip model with primary cells to model organ-specific radiation injury, establishing a model for radiation medical countermeasure development and further biomarker validation. Furthermore, we identified biomarkers that differentiate radiation dose and defined cell-specific targets for potential radiation mitigation therapies.Sep. 2024, Radiation research, 202(3) (3), 489 - 502, English, International magazineScientific journal
- BACKGROUND/AIM: Sorafenib and lenvatinib have long been used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Along with the development of systemic chemotherapy for HCC, the concept of conversion hepatectomy has recently become widespread. The present study aimed to assess the clinical outcomes of sorafenib and lenvatinib for HCC regarding the possibility of conversion hepatectomy in clinical practice. PATIENTS AND METHODS: A total of 295 patients with advanced HCC receiving sorafenib and lenvatinib, accounting for 306 treatments (sorafenib, n=157; lenvatinib, n=149, 11 patients received lenvatinib after sorafenib treatment) at five different institutions were enrolled. Patients were assessed for their clinical characteristics and therapeutic response using both Response Evaluation Criteria in Solid Tumors criteria (RECIST) and modified RECIST (mRECIST) criteria. Additionally, an indication of surgery after tyrosine kinase inhibitor administration was determined based on the tumor status of patients. RESULTS: The median survival times of patients treated with sorafenib and lenvatinib were 12.8 and 16.4 months, respectively, without significant difference (p=0.1645). The objective response rates (ORR) of sorafenib based on mRECIST and RECIST were 10.1% and 5.9%, respectively, and those of lenvatinib were 38.1% and 19.0%, respectively. Among the 306 treatments, two cases (sorafenib and lenvatinib, one each) underwent hepatectomy after systemic chemotherapy. CONCLUSION: Few cases with unresectable HCC were amenable to conversion hepatectomy after sorafenib and lenvatinib treatments due to the limited ORR by RECIST. Cautious approach must be taken when administering neoadjuvant chemotherapy aimed at conversion hepatectomy.Jul. 2024, Anticancer research, 44(7) (7), 3097 - 3103, English, International magazineScientific journal
- Radiation-related normal tissue injury sustained during cancer radiotherapy or in a radiological or mass casualty nuclear incident is a major health concern. Reducing the risk and mitigating consequences of radiation injury could have a broad impact on cancer patients and citizens. Efforts to discover biomarkers that can determine radiation dose, predict tissue damage, and aid medical triage are underway. Exposure to ionizing radiation causes changes in gene, protein, and metabolite expression that needs to be understood to provide a holistic picture for treating acute and chronic radiation-induced toxicities. We present evidence that both RNA (mRNA, microRNA, long noncoding RNA) and metabolomic assays may provide useful biomarkers of radiation injury. RNA markers may provide information on early pathway alterations after radiation injury that can predict damage and implicate downstream targets for mitigation. In contrast, metabolomics is impacted by changes in epigenetics, genetics, and proteomics and can be considered a downstream marker that incorporates all these changes to provide an assessment of what is currently happening within an organ. We highlight research from the past 10 years to understand how biomarkers may be used to improve personalized medicine in cancer therapy and medical decision-making in mass casualty scenarios.2023, Cytogenetic and genome research, 163(3-4) (3-4), 103 - 109, English, International magazineScientific journal
- [A Surgically Resected Case of Lung Metastases and Sister Mary Joseph's Nodule 24 Months after Operation for Pancreatic Cancer].Metastatic umbilical tumors from internal malignancy, known as Sister Mary Joseph's Nodule(SMJN), are a relatively rare prognostic sign. An 86-year-old woman with pancreatic body carcinoma underwent distal pancreatectomy for D2 lymph node removal in 20XX. No peritoneal dissemination was found at that time. Postoperative chemotherapy was not administered due to her age. Eighteen months postoperatively, tumor marker values increased and chest computed tomography(CT) revealed a single mass in the left lung. We resected the suspected lung metastasis. Positron emission tomography-CT performed 23 months postoperatively for increased tumor marker values after resection showed a 18F-fluorodeoxyglucose accumulation ofapproximately 4 cm in the umbilicus. The diagnosis by biopsy was umbilical metastasis ofthe pancreatic cancer. No recurrence or other metastases were found, so we performed an umbilical tumor resection and abdominoplasty 24 months postoperatively. No peritoneal dissemination was found in her abdomen and the ascites cytology was negative. The tumor was in the subcutaneous tissue; thus, the possibility of infiltration from the primary site or peritoneal dissemination was low. The tumor marker values decreased after the resection. She was followed-up without postoperative anticancer chemotherapy. However, the tumor marker values increased again, so chemotherapy was initiated. We report a case ofresection of pancreatic cancer and operation for lung and umbilical metastases of pancreatic cancer.Dec. 2019, Gan to kagaku ryoho. Cancer & chemotherapy, 46(13) (13), 2354 - 2356, Japanese, Domestic magazine
- PURPOSE: This study was designed to assess the potential role of the preoperative serum level of elastase 1 as a risk factor for recurrence in patients with resectable well-differentiated pancreatic neuroendocrine neoplasms (PanNETs). METHODS: Preoperative serum elastase 1 levels were measured in 53 patients with PanNETs who underwent complete tumor resection in two tertiary referral centers between January 2004 and June 2017. The preoperative elastase 1 levels were correlated with clinicopathological characteristics, including tumor recurrence and recurrence-free survival. RESULTS: The median elastase 1 level was 96 ng/dL (range: 21-990 ng/dL). Preoperative serum elastase 1 levels were significantly higher in those with tumors ≥ 20 mm in diameter (vs. < 20 mm, P = 0.018), WHO grade 2 (vs. grade 1, P = 0.035), and microscopic venous invasion (vs. without venous invasion, P = 0.039). The median preoperative serum level of elastase 1 was higher in patients with recurrence than in those without recurrence (251 vs. 80 ng/dL, P = 0.004). Receiver operating characteristic analysis of elastase 1 levels showed that a cutoff level of 250 ng/dL was associated with postoperative recurrence, with 63% sensitivity, 100% specificity, and 94% overall accuracy. Patients with higher elastase 1 levels showed significantly worse recurrence-free survival than that of those with lower levels (2-year recurrence-free survival rate: 25% and 92%, respectively, P < 0.001). CONCLUSIONS: Our data provide the first evidence that high preoperative elastase 1 levels may be a risk factor for postoperative recurrence in patients with resectable PanNETs.Oct. 2018, Annals of surgical oncology, 25(11) (11), 3358 - 3364, English, International magazineScientific journal
- BACKGROUND: The prognostic impact of pancreatic ductal adenocarcinoma (PDAC) invasion to the splenic vessel is controversial. OBJECTIVE: The aim of this study was to assess the clinical value of pathological and radiological splenic vessel invasion in PDACs of the body and tail. METHODS: Medical records of patients with resectable PDAC of the body and tail who underwent distal pancreatectomy between 2003 and 2016 at the Kobe University Hospital were retrospectively analyzed. RESULTS: Overall, 68 patients (29 female and 39 male patients) were enrolled. Pathologically determined splenic vein invasion (p-SV) and splenic artery invasion (p-SA) were identified in 21 (30.9%) and 5 (7.4%) patients, respectively. The p-SV (but not p-SA) was an independent prognostic factor in multivariate analysis (p = 0.009). On analysis of recurrence patterns, patients with PDAC positive for p-SV were at a higher risk for liver metastasis (p = 0.022); however, the associations were not significant for other recurrence patterns. Liver metastasis occurred earlier in patients who were positive for p-SV (p = 0.015). Preoperative computed tomography effectively diagnosed pathological vessel invasion (SV: sensitivity, 95.2%, specificity, 72.3%; SA: sensitivity, 100%, specificity, 84.1%). Radiological SV invasion remained significant in multivariate analysis regarding postoperative survival (p = 0.007), and was also associated with early liver metastases (p = 0.008). CONCLUSIONS: Pathological/radiological SV invasion were independent adverse prognostic factors associated with early liver metastasis in patients with PDAC of the body/tail. Assessment of these findings may be useful in determining optimal therapeutic options in these patients.Mar. 2018, Annals of surgical oncology, 25(3) (3), 638 - 646, English, International magazineScientific journal
- The immunoglobulin (Ig)-like cell adhesion molecule nectin-like molecule (Necl)-5/poliovirus receptor is up-regulated in many types of cancer cells and implicated in their abnormally enhanced cell proliferation and movement. We previously showed that Necl-5 cis-interacts with the platelet-derived growth factor (PDGF) receptor β through the extracellular region and enhances its signaling. Although this cis-interaction does not affect the PDGF-induced tyrosine phosphorylation of the receptor, the interaction of the cytoplasmic region of Necl-5 with sprouty2 and the regulation of its activity are required for the enhancement of the PDGF receptor β signaling by Necl-5. We investigated here the more detailed mechanism for this cis-interaction of Necl-5 with the PDGF receptor β. Necl-5 contains three Ig-like domains and the PDGF receptor β contains five Ig-like domains at their extracellular regions. We showed here that the third Ig-like domain of Necl-5 cis-interacted with the fifth Ig-like domain of the PDGF receptor β. The recombinant protein of the third Ig-like domain of Necl-5 inhibited the cis-interaction of full-length Necl-5 with the PDGF receptor β and the PDGF-induced activation of the ERK signaling pathway that was enhanced by Necl-5. These results revealed the novel roles of the third Ig-like domain of Necl-5 and the fifth Ig-like domain of the PDGF receptor β in its signaling.Mar. 2018, Genes to cells : devoted to molecular & cellular mechanisms, 23(3) (3), 214 - 224, English, International magazineScientific journal
- [A Surgical Resected Case of VIPoma with Para-Aortic Lymph Node Involvement].A 72-year-old woman had severe watery diarrhea and weight loss. Computed tomography demonstrated a 55mm tumor in pancreatic tail with enlargement of para-aortic lymph nodes. There was no apparent liver metastasis. Endoscopic ultrasound demonstrated a well-circumscribed heterogenous tumor, which was diagnosed neuroendocrine tumor by endoscopic ultrasound-guided fine needle aspiration biopsy. For suspected VIPoma with para-aortic lymph node involvement, distal pancreatectomy and para-aortic lymphadenectomy was performed. The tumor was diagnosed as VIPoma by immunohistochemistry. The diarrhea improved after surgery. No evidence of recurrence was detected after a follow-up of 11 months.Nov. 2017, Gan to kagaku ryoho. Cancer & chemotherapy, 44(12) (12), 1976 - 1978, Japanese, Domestic magazine
- The ligand-induced dimerization of cell surface single-transmembrane receptors is essential for their activation. However, physiological molecules that inhibit their dimerization and activation have not been identified. ErbB3 dimerizes with ErbB2 upon binding of heregulin (HRG) to ErbB3, causing the ErbB2-catalyzed tyrosine phosphorylation of ErbB3, which leads to the activation of the signalling pathways for cell movement and survival. Genetic disorders of this receptor cause tumorigenesis and metastasis of cancers. We show here that nectin-like molecule-4/cell adhesion molecule 4, known to serve as a tumour suppressor, interacts with ErbB3 in the absence of HRG and inhibits the HRG-induced dimerization of ErbB3 with ErbB2 and its activation. The third immunoglobulin-like domain of nectin-like molecule-4 cis-interacts with the extracellular domain 3 of ErbB3. We describe here a novel regulatory mechanism for the activation and signalling of cell surface single-transmembrane receptors.Sep. 2017, Scientific reports, 7(1) (1), 11375 - 11375, English, International magazineScientific journal
- We report a case of an internal hernia through a transverse mesocolon defect after laparoscopic distal pancreatectomy. The patient was a 58-year-old man with an intraductal papillary mucinous neoplasm of the pancreatic body who underwent laparoscopic distal pancreatectomy. During surgery, an approximately 5-cm defect in the transverse mesocolon was inadvertently made. The defect was not closed as it was thought to be large enough to preclude incarceration. However, the patient developed a bowel obstruction 2 months postoperatively. Laparotomy revealed that a loop of the proximal jejunum herniated through the defect and was adherent to the stapled pancreatic stump. An additional loop of the jejunum was herniated through the narrowed mesenteric defect. To our knowledge, this is the first case of an internal hernia through a transverse mesocolon defect after laparoscopic distal pancreatectomy.May 2017, Asian journal of endoscopic surgery, 10(2) (2), 187 - 190, English, Domestic magazineScientific journal
- Cell-surface cytokine receptors are regulated by their cis-interacting stimulatory and inhibitory co-receptors. We previously showed that the Ig-like cell-adhesion molecule nectin-4 cis-interacts with the prolactin receptor through the extracellular region and stimulates prolactin-induced prolactin receptor activation and signaling, resulting in alveolar development in the mouse mammary gland. However, it remains unknown how this interaction stimulates these effects. We show here that the cis-interaction of the extracellular region of nectin-4 with the prolactin receptor was not sufficient for eliciting these effects and that the cytoplasmic region of nectin-4 was also required for this interaction. The cytoplasmic region of nectin-4 directly interacted with suppressor of cytokine signaling 1 (SOCS1), but not SOCS3, JAK2, or STAT5a, and inhibited the interaction of SOCS1 with JAK2, eventually resulting in the increased phosphorylation of STAT5a. The juxtamembrane region of nectin-4 interacted with the Src homology 2 domain of SOCS1. Both the interaction of nectin-4 with the extracellular region of the prolactin receptor and the interaction of SOCS1 with the cytoplasmic region of nectin-4 were required for the stimulatory effect of nectin-4 on the prolactin-induced prolactin receptor activation. The third Ig-like domain of nectin-4 and the second fibronectin type III domain of the prolactin receptor were involved in this cis-interaction, and both the extracellular and transmembrane regions of nectin-4 and the prolactin receptor were required for this direct interaction. These results indicate that nectin-4 serves as a stimulatory co-receptor for the prolactin receptor by regulating the feedback inhibition of SOCS1 in the JAK2-STAT5a signaling pathway.Apr. 2017, The Journal of biological chemistry, 292(17) (17), 6895 - 6909, English, International magazineScientific journal
- Mammary gland development is induced by the actions of various hormones to form a structure consisting of collecting ducts and milk-secreting alveoli, which comprise two types of epithelial cells known as luminal and basal cells. These cells adhere to each other by cell adhesion apparatuses whose roles in hormone-dependent mammary gland development remain largely unknown. Here we identified a novel cell adhesion apparatus at the boundary between the luminal and basal cells in addition to desmosomes. This apparatus was formed by the trans-interaction between the cell adhesion molecules nectin-4 and nectin-1, which were expressed in the luminal and basal cells, respectively. Nectin-4 of this apparatus further cis-interacted with the prolactin receptor in the luminal cells to enhance the prolactin-induced prolactin receptor signaling for alveolar development with lactogenic differentiation. Thus, a novel nectin-mediated cell adhesion apparatus regulates the prolactin receptor signaling for mammary gland development.Mar. 2016, The Journal of biological chemistry, 291(11) (11), 5817 - 5831, English, International magazineScientific journal
- OBJECTIVES: The aim of this study was to determine the incidence rate and clinical features of second primary pancreatic ductal carcinoma (SPPDC) in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma (PDC). METHODS: Data of patients undergoing R0 resection for PDC at a single high-volume center were reviewed. SPPDC was defined as a tumor in the remnant pancreas after R0 resection for PDC, and SPPDC met at least one of the following conditions: 1) the time interval between initial pancreatectomy and development of a new tumor was 3 years or more; 2) the new tumor was not located in contact with the pancreatic stump. We investigated the clinical features and treatment outcomes of patients with SPPDC. RESULTS: This study included 130 patients who underwent surgical resection for PDC between 2005 and 2014. Six (4.6%) patients developed SPPDC. The cumulative 3- and 5-year incidence rates were 3.1% and 17.7%, respectively. Four patients underwent remnant pancreatectomy for SPPDC. They were diagnosed with the disease in stage IIA or higher and developed recurrence within 6 months after remnant pancreatectomy. One patient received carbon ion radiotherapy and survived 45 months. One patient refused treatment and died 19 months after the diagnosis of SPPDC. CONCLUSIONS: The incidence rate of SPPDC is not negligible, and the cumulative 5-year incidence rate of SPPDC is markedly high. Post-operative surveillance of the remnant pancreas is critical for the early detection of SPPDC, even in long-term survivors after PDC resection.2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 16(4) (4), 615 - 20, English, International magazineScientific journal
- Jun. 2015, PLOS ONE, 10(6) (6), EnglishScientific journal
- 金原出版(株), Jul. 2026, 手術, 80(8) (8), 1185 - 1191, Japanese
- (一社)日本膵臓学会, Jun. 2026, 膵臓, 41(3) (3), A170 - A170, JapaneseExpect the unexpected 留学のススメ
- (一社)日本膵臓学会, Jun. 2026, 膵臓, 41(3) (3), A320 - A320, Japanese膵機能温存・縮小手術の短期および長期成績 低侵襲脾温存尾側膵切除におけるKimura法とWarshaw法の短期および長期成績の比較
- (一社)日本内視鏡外科学会, Dec. 2022, 日本内視鏡外科学会雑誌, 27(7) (7), 50 - 50, Japaneseロボット支援手術時代における技術認定制度の在り方とは? ロボット支援膵切除時代における技術認定制度の役割と問題点
- (株)癌と化学療法社, Dec. 2021, 癌と化学療法, 48(13) (13), 1573 - 1575, JapaneseA Case of Myeloid Sarcoma in the Small Intestine Presenting with Intussusception
- 日本臨床外科学会, Oct. 2021, 日本臨床外科学会雑誌, 82(増刊) (増刊), S1297 - S1297, Japanese十二指腸穿破を伴う主膵管型膵管内乳頭粘液性腺癌に対して膵全摘術を施行した一例
- 日本臨床外科学会, Oct. 2021, 日本臨床外科学会雑誌, 82(増刊) (増刊), S1312 - S1312, JapaneseS状結腸腹膜垂による絞扼性腸閉塞に対し腹腔鏡下アプローチによる腸閉塞解除術に成功した1例
- (一社)日本大腸肛門病学会, Sep. 2021, 日本大腸肛門病学会雑誌, 74(9) (9), A211 - A211, Japanese直腸癌術後腹膜播種再発と鑑別が困難であった腹部放線菌症の1例
- (一社)日本消化器外科学会, Jul. 2021, 日本消化器外科学会総会, 76回(Supplement1) (Supplement1), P286 - 3, Japanese胸部食道癌に対する胸骨後経路再建術後に内胸動脈仮性瘤破裂を来した1例
- 2021, 日本大腸肛門病学会雑誌(Web), 74(9) (9)直腸癌術後腹膜播種再発と鑑別が困難であった腹部放線菌症の1例
- (一社)日本消化器外科学会, Dec. 2020, 日本消化器外科学会総会, 75回(Supplement1) (Supplement1), S12 - 6, Japanese胆嚢管から右肝管が分岐する胆道破格を有する急性胆嚢炎の1例
- (一社)日本消化器外科学会, Dec. 2020, 日本消化器外科学会総会, 75回(Supplement1) (Supplement1), S12 - 7, Japanese十二指腸傍乳頭憩室の膵内胆管穿破による胆道出血に対して膵頭十二指腸切除術を施行した一例
- (一社)日本外科学会, Aug. 2020, 日本外科学会定期学術集会抄録集, 120回, DP - 6, Japanese胃癌切除術後の無再発生存及び全生存予測におけるE-PASSの有用性の検討
- (一社)日本腹部救急医学会, Feb. 2020, 日本腹部救急医学会雑誌, 40(2) (2), 295 - 295, Japanese小児膿瘍形成性虫垂炎に対する当院での治療成績の検討
- (一社)日本腹部救急医学会, Feb. 2020, 日本腹部救急医学会雑誌, 40(2) (2), 404 - 404, Japanese当院のopen abdominal managementにおけるABTHERAの使用経験
- (株)癌と化学療法社, Dec. 2019, 癌と化学療法, 46(13) (13), 2354 - 2356, Japanese
- (一社)日本内視鏡外科学会, Dec. 2019, 日本内視鏡外科学会雑誌, 24(7) (7), SF051 - 4, Japanese当院における腹腔鏡下胆嚢摘出術後胆汁漏の検討R
- (一社)日本内視鏡外科学会, Dec. 2019, 日本内視鏡外科学会雑誌, 24(7) (7), MO091 - 4, Japanese正中弓状靱帯圧迫症候群に対して腹腔鏡下弓状靱帯切除術を施行した症例
- (一社)日本Acute Care Surgery学会, Oct. 2019, Japanese Journal of Acute Care Surgery (Web), 9(1) (1), 157 - 157, JapaneseCurrent Status of Emergency Lapaloscopic Surgery in Our Hospital
- (一社)日本Acute Care Surgery学会, Oct. 2019, Japanese Journal of Acute Care Surgery, 9(1) (1), 169 - 169, Japanese当院でのフレイルチェストに対する観血的肋骨整復固定術の現状
- 日本臨床外科学会, Oct. 2019, 日本臨床外科学会雑誌, 80(増刊) (増刊), 729 - 729, Japanese腹腔鏡下低位前方切除術後の骨盤部腸間膜欠損部に生じた内ヘルニアによるイレウスを腹腔鏡下に解除した一例
- 日本臨床外科学会, Oct. 2019, 日本臨床外科学会雑誌, 80(増刊) (増刊), 907 - 907, Japanese術前に診断し得たabdominal cocoonによる小腸イレウスの1例
- 日本臨床外科学会, Oct. 2019, 日本臨床外科学会雑誌, 80(増刊) (増刊), 913 - 913, Japanese下腸間膜静脈に化膿性門脈炎を呈したS状結腸憩室穿通の1例
- (一社)日本腹部救急医学会, Feb. 2019, 日本腹部救急医学会雑誌, 39(2) (2), 369 - 369, Japanese当院における虫垂炎の術式と合併症についての検討
- (一社)日本腹部救急医学会, Feb. 2019, 日本腹部救急医学会雑誌, 39(2) (2), 389 - 389, JapaneseTAE後に胆汁性腹膜炎を呈した肝損傷IIIbに対する腹腔鏡手術の試み
- (一社)日本腹部救急医学会, Feb. 2019, 日本腹部救急医学会雑誌, 39(2) (2), 439 - 439, Japanese腹腔鏡下腹会陰式直腸切断術後に5mmポートサイトヘルニア嵌頓を発症した1例
- (一社)日本腹部救急医学会, Feb. 2019, 日本腹部救急医学会雑誌, 39(2) (2), 463 - 463, Japanese当院における緊急手術での腸吻合に関する検討
- 2019, 日本物理学会講演概要集(CD-ROM), 74(2) (2)ホウ素をドープしたヘテロ接合をもつグラフェンナノリボンのギャップ内状態
- (一社)日本内視鏡外科学会, Dec. 2018, 日本内視鏡外科学会雑誌, 23(7) (7), OS121 - 4, Japanese高齢者急性胆嚢炎における早期手術症例と待機手術症例の比較検討
- (一社)日本内視鏡外科学会, Dec. 2018, 日本内視鏡外科学会雑誌, 23(7) (7), OS222 - 5, Japanese安全で円滑な腹腔鏡下手術のための手術室スタッフの知識・技術の向上に向けた取り組み
- 日本臨床外科学会, Oct. 2018, 日本臨床外科学会雑誌, 79(増刊) (増刊), 437 - 437, Japanese当院の胃SMTに対する腹腔鏡・内視鏡合同手術(LECS)の現状と課題
- 日本臨床外科学会, Oct. 2018, 日本臨床外科学会雑誌, 79(増刊) (増刊), 833 - 833, Japanese胃癌術後に発症した癌性髄膜炎
- (一社)日本消化器外科学会, Jul. 2018, 日本消化器外科学会総会, 73回(Supplement1) (Supplement1), 398 - 398, Japanese地域中核病院における高齢者大腸癌手術のPOSSUMを用いた合併症発生率および予後の検討
- (一社)日本消化器外科学会, Jul. 2018, 日本消化器外科学会総会, 73回(Supplement1) (Supplement1), 490 - 490, Japanese術前血清エラスターゼ-1値による膵頭十二指腸切除術後の膵液瘻の予測
- (一社)日本膵臓学会, May 2018, 膵臓, 33(3) (3), 570 - 570, Japanese術前診断に苦慮したpancreatobiliary type invasive IPMCの一例
- (一社)日本膵臓学会, May 2018, 膵臓, 33(3) (3), 658 - 658, JapaneseMEN1症例に生じたインスリノーマに対し、術中SASI testを行い核出術で治療しえた二例
- (一社)日本移植学会, May 2018, 移植, 53(1) (1), 71 - 77, Japanese
- (一社)日本外科学会, Apr. 2018, 日本外科学会定期学術集会抄録集, 118回, 1456 - 1456, Japanese診断に審査腹腔鏡が有用であった大網原発巨大脂肪腫による大網捻転症の一例
- (一社)日本外科学会, Apr. 2018, 日本外科学会定期学術集会抄録集, 118回, 2438 - 2438, Japanese術前Elastase 1高値は膵神経内分泌腫瘍の予後不良因子である
- 2018, 移植(Web), 53(1) (1)Acute graft-versus-host disease following simultaneous pancreas-kidney transplantation: a review of the literature
- (株)癌と化学療法社, Nov. 2017, 癌と化学療法, 44(12) (12), 1976 - 1978, Japanese
- 日本臨床外科学会, Oct. 2017, 日本臨床外科学会雑誌, 78(増刊) (増刊), 493 - 493, Japanese地域中核病院における高齢者大腸癌手術のPOSSUMを用いた合併症発生率および予後の検討
- 日本臨床外科学会, Oct. 2017, 日本臨床外科学会雑誌, 78(増刊) (増刊), 497 - 497, Japanese膵癌に対するD2郭清を伴う腹腔鏡下膵体尾部切除(LAP-DPD2)の導入と当科の標準手技
- (一社)日本消化器外科学会, Oct. 2017, 日本消化器外科学会雑誌, 50(Suppl.2) (Suppl.2), 230 - 230, Japanese膵管に沿った曲面任意多段面再構成画像(Curved MPR)の有用性
- (一社)日本消化器外科学会, Oct. 2017, 日本消化器外科学会雑誌, 50(Suppl.2) (Suppl.2), 232 - 232, Japanese膵体尾部癌における脾静脈浸潤は早期肝転移再発のリスク因子である
- (一社)日本移植学会, Aug. 2017, 移植, 52(総会臨時) (総会臨時), 338 - 338, Japanese当院における膵移植後社会復帰の現状と問題点
- (一社)日本膵臓学会, May 2017, 膵臓, 32(3) (3), 474 - 474, Japanese膵神経内分泌腫瘍における主膵管浸潤の臨床的意義
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, SF - 3, Japanese膵神経内分泌腫瘍における術前主膵管狭窄は予後不良因子である
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, PS - 8, Japanese高齢膵癌患者に対する切除成績と課題
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, PS - 3, Japanesesoft pancreasの膵空腸吻合手技と残膵内分泌能の評価
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, PS - 1, Japanese膵癌術前精査におけるEOB-MRIと審査腹腔鏡の意義
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, PS - 4, Japanese腹腔鏡下脾動静脈温存脾温存膵体尾部切除術の成績と課題
- 2017, 日本消化器外科学会雑誌(Web), 50(Supplement2) (Supplement2)膵体尾部癌における脾静脈浸潤は早期肝転移再発のリスク因子である
- 2017, 日本消化器外科学会雑誌(Web), 50(Supplement2) (Supplement2)膵管に沿った曲面任意多段面再構成画像(Curved MPR)の有用性
- 2017, 日本膵切研究会プログラム・抄録集, 44th膵頭十二指腸切除後における胃内容排出遅延発症リスクの解析:長期腹腔ドレーン留置の影響について
- 2017, 日本膵・膵島移植研究会プログラム・抄録集, 44th膵腎同時移植後グラフト十二指腸穿孔により膵グラフトを摘出し,膵臓再移植を行った1例
- 2017, 日本膵切研究会プログラム・抄録集, 44th膵頭十二指腸切除における膵管不完全外瘻ドレナージ
- 2017, 日本膵切研究会プログラム・抄録集, 44th当科における切除可能膵癌に対する術前治療の経験
- (一社)日本内視鏡外科学会, Dec. 2016, 日本内視鏡外科学会雑誌, 21(7) (7), DP48 - 7, Japanese腹腔鏡下膵体尾部切除術後の横行結腸間膜欠損部内ヘルニアの一例
- (一社)日本消化器外科学会, Nov. 2016, 日本消化器外科学会雑誌, 49(Suppl.2) (Suppl.2), 217 - 217, Japanese膵切除による耐糖能の変化
- 日本臨床外科学会, Oct. 2016, 日本臨床外科学会雑誌, 77(増刊) (増刊), 442 - 442, Japanese消化器神経内分泌腫瘍に対する外科治療の意義 膵神経内分泌腫瘍(PNET)リンパ節転移の術前リスク評価と治療方針
- (一社)日本移植学会, Sep. 2016, 移植, 51(総会臨時) (総会臨時), 419 - 419, Japanese十二指腸グラフトが起因した縫合不全の2例
- (一社)日本肝胆膵外科学会, Jun. 2016, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 28回, 481 - 481, Japanese膵NETに対する治療戦略 リンパ節転移に関わる因子の検討
- (一社)日本肝胆膵外科学会, Jun. 2016, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 28回, 542 - 542, Japanese膵切除後腹腔内出血に対する治療戦略 当院で経験した35例からのフィードバック
- (一社)日本肝胆膵外科学会, Jun. 2016, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 28回, 548 - 548, Japanese術後24年目に腹膜播種、肝転移再発を来たしたと考えられる膵solid pseudopapillary neoplasmの1例
- 日本外科系連合学会, May 2016, 日本外科系連合学会誌, 41(3) (3), 406 - 406, Japanese各科手術におけるエネルギーデバイス使用の現状 ソフト凝固を用いた腹腔鏡下脾温存尾側膵切除手技
- 2016, 日本消化器外科学会雑誌(Web), 49(Supplement2) (Supplement2)膵切除による耐糖能の変化
- (一社)日本内視鏡外科学会, Dec. 2015, 日本内視鏡外科学会雑誌, 20(7) (7), OS192 - 3, Japaneseソフト凝固とイオアドバンス電極を用いた腹腔鏡下脾温存尾側膵切除(Lap-SPDP)手技
- (一社)日本癌学会, Oct. 2015, 日本癌学会総会記事, 74回, P - 2054, English転移乳がん細胞におけるCXCR4の発現低下とがん休眠との関連
- (一社)日本移植学会, Sep. 2015, 移植, 50(総会臨時) (総会臨時), 280 - 280, Japanese膵臓移植後GVHDにおけるHLA 0 mismatchの意義
- (一社)日本組織適合性学会, Aug. 2015, MHC: Major Histocompatibility Complex, 22(2Suppl.) (2Suppl.), 105 - 105, English
- (一社)日本消化器外科学会, Jul. 2014, 日本消化器外科学会総会, 69回(Supplement1) (Supplement1), P - 3, Japanese確実な膵管空腸粘膜縫合と吻合部後面の被覆に留意した膵空腸吻合の工夫
- (一社)日本消化器外科学会, Jul. 2014, 日本消化器外科学会総会, 69回(Supplement1) (Supplement1), P - 1, Japanese小腸穿孔に対するTチューブ留置による一治療例
- (一社)日本消化器外科学会, Jul. 2014, 日本消化器外科学会総会, 69回(Supplement1) (Supplement1), P - 7, Japanese転移性大腸癌に対するOX stop & goを念頭においたXELOX+BV療法の有用性について
- (一社)日本消化器外科学会, Jul. 2014, 日本消化器外科学会総会, 69回(Supplement1) (Supplement1), P - 1, Japanese上直腸動脈温存S状結腸切除術 非温存症例との短期、長期成績の比較
- (一社)日本肝胆膵外科学会, Jun. 2014, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 525 - 525, Japanese確実な膵管空腸粘膜縫合と吻合部後面の被覆に留意した膵空腸吻合の工夫
- (一社)日本肝胆膵外科学会, Jun. 2014, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 528 - 528, Japanese局所進行膵粘液性嚢胞腺癌の1例
- (一社)日本外科学会, Mar. 2014, 日本外科学会雑誌, 115(臨増2) (臨増2), 588 - 588, Japanese腹腔鏡下肝嚢胞開窓術におけるICG蛍光法による術中胆道造影の有用性
- (一社)日本内視鏡外科学会, Nov. 2013, 日本内視鏡外科学会雑誌, 18(7) (7), 488 - 488, Japanese当院における単孔式大腸切除術
の現状 - (一社)日本内視鏡外科学会, Nov. 2013, 日本内視鏡外科学会雑誌, 18(7) (7), 531 - 531, Japanese腹腔鏡下開窓術においてインドシアニングリーン蛍光法が有用であった巨大肝嚢胞の1例
- (一社)日本内視鏡外科学会, Nov. 2013, 日本内視鏡外科学会雑誌, 18(7) (7), 725 - 725, Japanese当科における腹腔鏡下鼠径ヘルニア手術(TAPP法)の検討
- 日本臨床外科学会, Oct. 2013, 日本臨床外科学会雑誌, 74(増刊) (増刊), 507 - 507, Japanesebipolar scissorsを用いた上直腸動脈温存S状結腸切除術
- 日本臨床外科学会, Oct. 2013, 日本臨床外科学会雑誌, 74(増刊) (増刊), 673 - 673, Japanese出血性ショックをきたした小腸憩室出血の一例
- 日本臨床外科学会, Oct. 2013, 日本臨床外科学会雑誌, 74(増刊) (増刊), 914 - 914, Japanese門脈内腫瘍塞栓にて再発を来たした胃未分化癌の1例
- (一社)日本消化器外科学会, Oct. 2013, 日本消化器外科学会雑誌, 46(Suppl.2) (Suppl.2), 199 - 199, Japanese腫瘍破裂で発症し肝細胞癌と鑑別困難であった肝原発類上皮血管内皮腫の1例
- (一社)日本消化器外科学会, Oct. 2013, 日本消化器外科学会雑誌, 46(Suppl.2) (Suppl.2), 243 - 243, Japanese転移性大腸癌に対する1st line化学療法としてのSOX±分子標的薬療法の治療成績
- (一社)日本癌治療学会, Sep. 2013, 日本癌治療学会誌, 48(3) (3), 1415 - 1415, Japanese転移性大腸癌に対するXELOX+BV療法→XEL+BV維持療法の治療戦略
- (一社)日本胆道学会, Aug. 2013, 胆道, 27(3) (3), 643 - 643, Japanese腹腔鏡下肝嚢胞開窓術においてインドシアニングリーン蛍光法が有用であった巨大肝嚢胞の1例
- (一社)日本消化器外科学会, Jul. 2013, 日本消化器外科学会総会, 68回(Supplement1) (Supplement1), P - 8, Japanesebipolar scissorsを用いたリンパ節廓清と血管への影響
- (一社)日本消化器外科学会, Jul. 2013, 日本消化器外科学会総会, 68回(Supplement1) (Supplement1), P - 4, Japanese腹腔鏡下肝嚢胞開窓術においてインドシアニングリーン蛍光法が有用であった巨大肝嚢胞の1例
- (一社)日本肝胆膵外科学会, Jun. 2013, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 25回, 320 - 320, Japanese腹腔鏡下肝嚢胞開窓術においてインドシアニングリーン蛍光法が有用であった巨大肝嚢胞の1例
- (一社)日本外科学会, Mar. 2013, 日本外科学会雑誌, 114(臨増2) (臨増2), 510 - 510, Japanese直腸癌に対する腹腔鏡下手術 切離吻合の工夫
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 393 - 393, Japanese当院における単孔式大腸切除術の現状と将来
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 418 - 418, Japanese単孔式腹腔鏡下S状結腸切除術における上直腸動脈温存D3郭清
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 579 - 579, Japanese腹腔鏡下ラジオ波焼灼術におけるNon-Trocar Techniqueの有用性
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 650 - 650, Japanese腹腔鏡下左側大腸切除術における左結腸動脈温存操作の工夫
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 726 - 726, Japanese上直腸動脈温存S状結腸切除術 bipolar scissorsを用いた工夫
- (一社)日本癌治療学会, Oct. 2012, 日本癌治療学会誌, 47(3) (3), 2339 - 2339, JapaneseBevacizumab導入後の治療期間(1次)延長とKRAS別治療期間
- 日本臨床外科学会, Oct. 2012, 日本臨床外科学会雑誌, 73(増刊) (増刊), 436 - 436, Japanese当院におけるReduced Port Surgeryとしての
- 日本臨床外科学会, Oct. 2012, 日本臨床外科学会雑誌, 73(増刊) (増刊), 641 - 641, Japanese腹腔鏡下ラジオ波焼灼術におけるNon-Trocar Techniqueの有用性
- 日本臨床外科学会, Oct. 2012, 日本臨床外科学会雑誌, 73(増刊) (増刊), 950 - 950, Japanese肝細胞癌の腫瘍播種に対し3度の局所切除を実施し長期生存が得られた1例
- (一社)日本糖尿病学会, Aug. 2012, 糖尿病, 55(8) (8), 653 - 653, Japanese高血糖に伴った糖尿病性舞踏病の1例
- 2012, 日本臨床外科学会雑誌, 73当院におけるReduced Port Surgeryとしての〈TANKO+1〉
- 日本臨床外科学会, Oct. 2011, 日本臨床外科学会雑誌, 72(増刊) (増刊), 778 - 778, Japanese胃癌術後補助化学療法の適応についての検討
